Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:associated_with |
gptkb:deep_vein_thrombosis
pulmonary embolism phocomelia |
| gptkbp:casnumber |
50-35-1
|
| gptkbp:cause |
birth defects
|
| gptkbp:chemical_formula |
C13 H10 N2 O4 S
|
| gptkbp:class |
immunomodulatory drug
|
| gptkbp:clinical_trial |
ongoing for various conditions
|
| gptkbp:composed_by |
can be synthesized from glutamic acid
can be synthesized from phthalimide |
| gptkbp:contraindication |
pregnancy
breastfeeding |
| gptkbp:developed_by |
gptkb:Chemie_Grünenthal
treating insomnia treating morning sickness |
| gptkbp:discovered_by |
gptkb:Germany
|
| gptkbp:dissolved |
soluble in organic solvents
poorly soluble in water |
| gptkbp:first_introduced |
gptkb:1957
|
| gptkbp:has_impact_on |
quality of life
apoptosis cell differentiation cell growth cognitive function inflammation pain relief anxiety reduction sleep regulation weight gain angiogenesis immune system neuroprotection appetite stimulation fatigue reduction mood stabilization nausea reduction |
| https://www.w3.org/2000/01/rdf-schema#label |
thalidomide
|
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
for side effects
|
| gptkbp:market_position |
gptkb:1961
|
| gptkbp:marketed_as |
gptkb:Thalomid
multiple countries |
| gptkbp:mechanism_of_action |
inhibits TNF-alpha production
|
| gptkbp:reintroduced_for |
gptkb:cancer_treatment
HIV treatment |
| gptkbp:related_to |
gptkb:lenalidomide
gptkb:pomalidomide |
| gptkbp:side_effect |
rash
drowsiness constipation peripheral neuropathy |
| gptkbp:used_for |
treating leprosy
treating multiple myeloma |
| gptkbp:used_in |
combination therapy
clinical research |
| gptkbp:weight |
258.33 g/mol
|
| gptkbp:bfsParent |
gptkb:Lenalidomide
gptkb:Pomalidomide gptkb:Pomalyst gptkb:Thalomid |
| gptkbp:bfsLayer |
5
|